drugset / Trial / NCT05412329
Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple Myeloma
Phase 1
Unknown
9 enrolled
Shanghai Changzheng Hospital
Gracell Biotechnologies (Shanghai) Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, non-randomized, open-label study to confirm the RP2D (recommended phase 2 dose) of GC012F injection in patients with Relapsed/Refractory multiple myeloma (RRMM).
Timeline
- Start
- 2022-06-13
- Primary completion
- 2024-06-01
- Completion
- 2024-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GC012F | Cell therapy | 100000 cells/kg | Intravenous |
| Subject | GC012F | Cell therapy | 200000 cells/kg | Intravenous |
| Subject | GC012F | Cell therapy | 300000 cells/kg | Intravenous |